Biogen BG-12 meets goal in reducing relapsing MS, but will it stack up against Teva’s laquinimod?
This article was originally published in Scrip
Executive Summary
Investors on 11 April were upbeat about top-line results from Biogen Idec's Phase III DEFINE trial, which showed that single-agent BG-12 (dimethyl fumarate) significantly reduced relapsing-remitting multiple sclerosis (RRMS) – meeting the study's primary endpoint.